Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Chang, Qing ^a   Chapman, Mark S ^b   Miner, Jeffrey N ^b   Hedley, David W ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Ardea Biosciences Inc   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 869766; PROTEIN S6; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; RDEA 119; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BROXURIDINE; DIPHENYLAMINE; DRUG DERIVATIVE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; N (3,4 DIFLUORO 2 (2 FLUORO 4 IODOPHENYLAMINO) 6 METHOXYPHENYL) 1 (2,3 DIHYDROXYPROPYL)CYCLOPROPANE 1 SULFONAMIDE; N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; DRUG ANTAGONISM; MALE; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; DIPHENYLAMINE; ENZYME INHIBITORS; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES;

EID: 77957164869     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-515     Document Type: Article

References (20)

1. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
2. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450. 10.1016/S1535-6108(03)00309-X, 14706336.
3. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003, 162:1807-1815. 1868131, 12759238.
4. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz SB, McDaid HM. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007, 67:11300-11308. 10.1158/0008-5472.CAN-07-0702, 18056456.
5. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4:937-947. 10.1038/nrc1503, 15573115.
6. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009, 69:6839-6847. 10.1158/0008-5472.CAN-09-0679, 19706763.
7. Chang Q, Chen E, Hedley DW. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther 2009, 8:1893-1901.
8. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001, 7:3269-3275.
9. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005, 65:1497-1504. 10.1158/0008-5472.CAN-04-2940, 15735038.
10. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005, 331:295-302. 10.1016/j.bbrc.2005.03.166, 15845392.
11. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 2009, 100:1267-1276. 10.1038/sj.bjc.6604995, 2676548, 19319133.
12. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994, 54:6201-6209.
13. Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001, 61:7394-7398.
14. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006, 12:4652-4661. 10.1158/1078-0432.CCR-06-0113, 16899615.
15. Birle DC, Hedley DW. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol Cancer Ther 2006, 5:2494-2502. 10.1158/1535-7163.MCT-05-0504, 17041093.
16. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8:179-183. 10.1016/j.ccr.2005.08.008, 16169463.
17. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502. 10.1016/j.devcel.2007.03.020, 17419990.
18. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Perez-Soler R, Horwitz SB. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 2005, 65:2854-2860. 10.1158/0008-5472.CAN-04-4391, 15805287.
19. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res 2009, 15:5820-5828. 10.1158/1078-0432.CCR-08-3294, 19737956.
20. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010, 52:79-87. 10.1016/j.jhep.2009.10.008, 19910069.